EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prostate-specific Membrane Antigen–radioguided Surgery in an EMBARK-like Cohort of Patients with Oligorecurrent Hormone-sensitive Prostate Cancer: Delay in Systemic Treatment

Fabian Falkenbach, Flemming Lischewski, Sophie Knipper, Daniel Koehler, Pierre I Karakiewicz, Zhe Tian, Fred Saad, Derya Tilki, Lars Budäus, Thomas Steuber, Philipp Mandel, Mike Wenzel und 4 weitere

European Urology Focus · 2025

DOI: 10.1016/j.euf.2025.01.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Urology Focus, 2025. Verfasst von Fabian Falkenbach und 15 weiteren Autor:innen. Beteiligte Einrichtung: Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Cancer Prognostics and Health Outcomes Unit, Di…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy, Neoplasm Recurrence, Local, Surgery, Computer-Assisted. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We analyzed data for a cohort of 111 patients with EMBARK-like biochemical recurrence (BCR) of prostate cancer (prostate-specific antigen [PSA] doubling time ≤9 mo, PSA ≥1 ng/ml) after radical prostatectomy and localized oligorecurrence on prostate-specific membrane antigen (PSMA)-based imaging. All patients underwent PSMA-radioguided surgery (RGS). At PSMA-RGS, the median PSA was 1.95 ng/ml (interquartile range [IQR] 1.36-3.20) ng/ml and the median PSA doubling time was 4.0 mo (IQR 2.5-5.5). Clavien-Dindo grade >IIIa complications occurred in nine of 111 patients (8.1%). A complete biochemical response (cBR; PSA decline ≤0.2 ng/ml after PSMA-RGS) was observed in 53 patients (47.7%). In the cBR group (equivalent to the treatment suspension criterion in EMBARK), estimated survival rates at 2 yr were 49.9% (95% confidence interval [CI] 37.2-67.1%) for BCR-free survival and 65.2% (95% CI 52.2-81.4%) for treatment-free survival. A relevant proportion of our PSMA-RGS cohort with localized oligorecurrence on PSMA-based imaging fulfilled the EMBARK criteria. PSMA-RGS yielded meaningful biochemical responses that translated to long-lasting treatment-free periods. PATIENT SUMMARY: For some patients with prostate cancer and no evidence of metastasis on conventional imaging but high risk of metastatic progression, modern molecular imaging identifies small cancer deposits that can be removed via targeted surgery. This surgery led to a significant decrease in PSA (prostate-specific antigen) levels, which allowed a longer break from further treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatectomyNeoplasm Recurrence, LocalSurgery, Computer-AssistedGlutamate Carboxypeptidase IIAntigens, SurfaceHumansMaleAgedProstate-Specific AntigenMiddle AgedCohort StudiesRetrospective Studies

Stichwörter der Autor:innen

Biochemical recurrenceEMBARK trialEnzalutamideProstate-specific antigenProstate-specific membrane antigenRadioguided surgery

Substanzen

Prostate-Specific AntigenFOLH1 protein, humanGlutamate Carboxypeptidase IIAntigens, Surface

Autor:innen und Institutionen

  • Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Can…
  • Department of Urology, Technical University of Munich, Munich, Germany.
  • Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Vivantes Klinikum am Urban, Berlin, Germany.
  • Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada.
  • Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Zitieren

APA

Falkenbach, F., Lischewski, F., Knipper, S., Koehler, D., Karakiewicz, P. I., Tian, Z., Saad, F., Tilki, D., Budäus, L., Steuber, T., Mandel, P., Wenzel, M., Gschwend, J. E., Graefen, M., Heck, M. M., & Maurer, T. (2025). Prostate-specific Membrane Antigen–radioguided Surgery in an EMBARK-like Cohort of Patients with Oligorecurrent Hormone-sensitive Prostate Cancer: Delay in Systemic Treatment. European Urology Focus. https://doi.org/10.1016/j.euf.2025.01.006

Vancouver

Falkenbach F, Lischewski F, Knipper S, Koehler D, Karakiewicz PI, Tian Z, et al. Prostate-specific Membrane Antigen–radioguided Surgery in an EMBARK-like Cohort of Patients with Oligorecurrent Hormone-sensitive Prostate Cancer: Delay in Systemic Treatment. European Urology Focus. 2025. doi:10.1016/j.euf.2025.01.006

BibTeX
@article{Falkenbach2025,
  author = {Falkenbach, Fabian and Lischewski, Flemming and Knipper, Sophie and Koehler, Daniel and Karakiewicz, Pierre I and Tian, Zhe and Saad, Fred and Tilki, Derya and Budäus, Lars and Steuber, Thomas and Mandel, Philipp and Wenzel, Mike and Gschwend, Jürgen E and Graefen, Markus and Heck, Matthias M and Maurer, Tobias},
  title = {Prostate-specific Membrane Antigen–radioguided Surgery in an EMBARK-like Cohort of Patients with Oligorecurrent Hormone-sensitive Prostate Cancer: Delay in Systemic Treatment},
  journal = {European Urology Focus},
  year = {2025},
  doi = {10.1016/j.euf.2025.01.006}
}
Kostenlos starten →